Skip to Main Content

Paper Details

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.
Acta Neuropathol Commun
17
2022
AVAglio, CD45+, CD45+ immune cells, MMP2, MMP9, MMP9 mRNA, Patients, bevacizumab, glioblastoma, inflammatory cells, matrix metalloproteinase 2, patients, plasma MMP9, recurrent glioblastoma, tumor, tumor cells, tumor-infiltrating neutrophils
Author NameAffiliation
Josep GarciaF. Hoffmann-La Roche Ltd
Warren P MasonPrincess Margaret Hospital
Dominique Figarella-BrangerAix-Marseille University, CNRS
Dominique Figarella-Branger
  • 1 - 4

Datasets

Release 1.2